1. Home
  2. ALRN vs SPRO Comparison

ALRN vs SPRO Comparison

Compare ALRN & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALRN
  • SPRO
  • Stock Information
  • Founded
  • ALRN 2001
  • SPRO 2013
  • Country
  • ALRN United States
  • SPRO United States
  • Employees
  • ALRN N/A
  • SPRO N/A
  • Industry
  • ALRN Biotechnology: Pharmaceutical Preparations
  • SPRO Biotechnology: Pharmaceutical Preparations
  • Sector
  • ALRN Health Care
  • SPRO Health Care
  • Exchange
  • ALRN Nasdaq
  • SPRO Nasdaq
  • Market Cap
  • ALRN 76.9M
  • SPRO 63.0M
  • IPO Year
  • ALRN 2017
  • SPRO 2017
  • Fundamental
  • Price
  • ALRN $1.92
  • SPRO $1.04
  • Analyst Decision
  • ALRN Strong Buy
  • SPRO Buy
  • Analyst Count
  • ALRN 1
  • SPRO 3
  • Target Price
  • ALRN $19.00
  • SPRO $5.00
  • AVG Volume (30 Days)
  • ALRN 92.8K
  • SPRO 205.6K
  • Earning Date
  • ALRN 11-14-2024
  • SPRO 11-14-2024
  • Dividend Yield
  • ALRN N/A
  • SPRO N/A
  • EPS Growth
  • ALRN N/A
  • SPRO N/A
  • EPS
  • ALRN N/A
  • SPRO 0.06
  • Revenue
  • ALRN N/A
  • SPRO $106,455,000.00
  • Revenue This Year
  • ALRN N/A
  • SPRO N/A
  • Revenue Next Year
  • ALRN N/A
  • SPRO N/A
  • P/E Ratio
  • ALRN N/A
  • SPRO $16.37
  • Revenue Growth
  • ALRN N/A
  • SPRO 37.01
  • 52 Week Low
  • ALRN $1.61
  • SPRO $1.01
  • 52 Week High
  • ALRN $7.42
  • SPRO $1.89
  • Technical
  • Relative Strength Index (RSI)
  • ALRN 29.69
  • SPRO 28.87
  • Support Level
  • ALRN $1.85
  • SPRO $1.12
  • Resistance Level
  • ALRN $2.38
  • SPRO $1.20
  • Average True Range (ATR)
  • ALRN 0.30
  • SPRO 0.05
  • MACD
  • ALRN -0.01
  • SPRO -0.01
  • Stochastic Oscillator
  • ALRN 6.31
  • SPRO 8.33

About ALRN Aileron Therapeutics Inc.

Aileron Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing a novel class of therapeutics for the treatment of cancer and other diseases. The company's lead product candidate, ALRN-6924 is a novel chemoprotective medicine to treat and protect healthy cells in patients with cancer that harbors p53 mutations to reduce or eliminate chemotherapy-induced side effects. The company currently has two product candidates in clinical development, LTI-03 and LTI-01, and multiple candidates in preclinical development focused on fibrosis indications.

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Share on Social Networks: